Blog

Goutham Sunny: TILs may serve as valuable Prognostic Biomarkers in HER2+ mBC

Goutham Sunny/X

May 12, 2025, 09:16

Goutham Sunny: TILs may serve as valuable Prognostic Biomarkers in HER2+ mBC

Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X:

“A multicenter Italian study of 110 patients with HER2+ metastatic breast cancer (mBC) treated with pertuzumab, trastuzumab & taxane chemo found that high tumor-infiltrating lymphocytes (TILs >5%) were linked to longer progression-free and overall survival.

TILs were higher in primary tumors vs metastases (p=0.009) and varied by metastatic site. These findings suggest TILs may serve as valuable prognostic biomarkers in HER2+ mBC, warranting further prospective validation.”

More posts featuring Metastatic Breast Cancer on OncoDaily.

cancer fight against cancer Global fight against cancer Goutham Sunny HER2 MBC metastatic breast cancer OncoDaily Oncology pertuzumab Prognostic Biomarkers taxane TILs trastuzumab tumor infiltrating lymphocytes

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot

The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia